DE68923878D1 - Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide. - Google Patents

Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide.

Info

Publication number
DE68923878D1
DE68923878D1 DE68923878T DE68923878T DE68923878D1 DE 68923878 D1 DE68923878 D1 DE 68923878D1 DE 68923878 T DE68923878 T DE 68923878T DE 68923878 T DE68923878 T DE 68923878T DE 68923878 D1 DE68923878 D1 DE 68923878D1
Authority
DE
Germany
Prior art keywords
entry
row
gly
arg
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68923878T
Other languages
English (en)
Other versions
DE68923878T2 (de
Inventor
J Seilhamer
John Lewicki
Robert Scarborough
J Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios Nova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68923878(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scios Nova Inc filed Critical Scios Nova Inc
Application granted granted Critical
Publication of DE68923878D1 publication Critical patent/DE68923878D1/de
Publication of DE68923878T2 publication Critical patent/DE68923878T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C07K14/582—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
DE68923878T 1988-05-31 1989-05-31 Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide. Expired - Lifetime DE68923878T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20038388A 1988-05-31 1988-05-31
US20647088A 1988-06-14 1988-06-14
US29988089A 1989-01-19 1989-01-19
PCT/US1989/002373 WO1989012069A1 (en) 1988-05-31 1989-05-31 Recombinant techniques for production of novel natriuretic and vasodilator peptides

Publications (2)

Publication Number Publication Date
DE68923878D1 true DE68923878D1 (de) 1995-09-21
DE68923878T2 DE68923878T2 (de) 1995-12-21

Family

ID=27394150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68923878T Expired - Lifetime DE68923878T2 (de) 1988-05-31 1989-05-31 Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide.

Country Status (9)

Country Link
US (7) US5674710A (de)
EP (1) EP0418308B1 (de)
JP (1) JP2511160B2 (de)
AT (1) ATE126522T1 (de)
AU (1) AU3768189A (de)
CA (1) CA1339210C (de)
DE (1) DE68923878T2 (de)
IE (1) IE68889B1 (de)
WO (1) WO1989012069A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
JPH02222683A (ja) * 1989-02-22 1990-09-05 Dai Ichi Seiyaku Co Ltd 新規ｄｎａ
ATE124994T1 (de) * 1989-03-01 1995-07-15 Daiichi Pure Chemicals Co Ltd Physiologisch aktives polypeptid und dna.
JP2883903B2 (ja) * 1989-03-10 1999-04-19 塩野義製薬株式会社 新規生理活性ペプチド及びその用途
US7211380B1 (en) 1989-03-01 2007-05-01 Shionogi & Co., Ltd. Physiologically active polypeptide and DNA
US20020086843A1 (en) * 1989-03-01 2002-07-04 Daiichi Pure Chemicals Co., Ltd. Physiologically active polypeptide and DNA
JP3160276B2 (ja) * 1989-03-01 2001-04-25 塩野義製薬株式会社 新規ｃＤＮＡフラグメント
JP3264439B2 (ja) * 1989-03-10 2002-03-11 塩野義製薬株式会社 新規生理活性ペプチド及びその用途
JP3026354B2 (ja) * 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
JP3025672B2 (ja) * 1998-05-14 2000-03-27 塩野義製薬株式会社 新規生理活性ペプチド及びその用途
DK1698901T3 (da) * 1999-01-29 2008-12-08 Roche Diagnostics Gmbh Metode til at detektere N-terminalt proBNP
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP3346764B2 (ja) * 2000-12-05 2002-11-18 塩野義製薬株式会社 新規ｃＤＮＡフラグメント
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003270427A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US7135329B2 (en) * 2002-11-18 2006-11-14 Princeton Biomeditech Corporation Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
AU2003302087A1 (en) 2002-11-18 2004-06-15 Syn X Pharma, Inc. Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
US7109023B2 (en) * 2002-11-18 2006-09-19 Princeton Biomeditech Corporation Immunossay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients
SG159387A1 (en) 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US20060172929A1 (en) * 2003-01-13 2006-08-03 Gudrun Rappold-Hoerbrand Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
US7767419B2 (en) * 2003-02-04 2010-08-03 Nexus Dx, Inc. Calibrator for NT-proBNP immunoassay
WO2004076664A2 (en) * 2003-02-21 2004-09-10 University Of South Florida Vectors for regulating gene expression
WO2004097368A2 (en) * 2003-04-28 2004-11-11 Ciphergen Biosystems, Inc. Improved immunoassays
EP2308889B1 (de) 2003-06-20 2018-05-23 Mayo Foundation For Medical Education And Research Isoformen von Gehirn-Natriuretischem Peptid
US20070238676A1 (en) * 2003-12-04 2007-10-11 Mohapatra Shyam S Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
US20080182299A1 (en) * 2004-01-27 2008-07-31 Compugent Ltd. Novel brain natriuretic peptide variants and methods of use thereof
US7332569B2 (en) * 2004-01-27 2008-02-19 Compugen Ltd. Brain natriuretic peptide spliced variant
AU2005227870A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
PT1759001E (pt) 2004-04-21 2011-07-12 Enobia Pharma Inc Conjugados de libertação óssea e método de utilização dos mesmos para direccionar proteínas ao osso
AT500800B1 (de) * 2004-09-08 2008-07-15 Biomedica Medizinprodukte Gmbh Verfahren zur bestimmung von probnp
CA2579370A1 (en) * 2004-09-09 2006-03-23 Biosite Incorporated Methods and compositions for measuring canine bnp and uses thereof
US20060084114A1 (en) * 2004-10-15 2006-04-20 Yeo Kiang-Tech J Method for detecting cardiac collateral formation
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US7731965B2 (en) 2005-02-17 2010-06-08 Abbott Lab Human ring specific BNP antibodies
US20060280645A1 (en) * 2005-06-02 2006-12-14 Scott Sellers Method for terminal sterilization of transdermal delivery devices
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP1922336B1 (de) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybridpolypeptide mit auswählbaren eigenschaften
DE102005039608A1 (de) * 2005-08-19 2007-03-01 Ormecon Gmbh Zusammensetzung mit intrinsisch leitfähigem Polymer
WO2007041645A2 (en) * 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
CA2629438C (en) 2005-11-09 2014-02-25 Abbott Laboratories Human bnp immunospecific antibodies
US7939069B2 (en) 2005-11-09 2011-05-10 Abbott Laboratories Human BNP immunospecific antibodies
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
JP2009532385A (ja) * 2006-03-30 2009-09-10 パラティン・テクノロジーズ・インコーポレーテッド 線状ナトリウム利尿ペプチド構築物
CA2647143A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
CA2656990A1 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080070792A1 (en) 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
BRPI0716416A2 (pt) * 2006-08-08 2016-10-11 Mayo Foundation polipeptídeo substancialmente puro entre 37 e 47 besíduos de aminoácido de comprimento, ácido nucléico isolado, vetor: célula hospedeira e composição farmacêutica
US20080064045A1 (en) 2006-09-07 2008-03-13 Huaiqin Wu Biomarker fragments for the detection of human BNP
MY147793A (en) * 2006-09-13 2013-01-31 Enthone Article with a coating of electrically conductive polymer and precious/semiprecious metal and process for production thereof
JP5570415B2 (ja) * 2007-05-08 2014-08-13 アボット・ラボラトリーズ 他のペプチド型に対する交差反応性の低いヒトｂ型ナトリウム利尿ペプチドアッセイ
US8357656B2 (en) * 2007-09-15 2013-01-22 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-C agonists
EP2225374B1 (de) * 2007-11-26 2013-08-14 Novartis AG Verfahren zur erzeugung von alphaviruspartikeln
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
EP3378951B1 (de) 2008-09-20 2020-05-13 The Board of Trustees of the Leland Stanford Junior University Nicht invasive diagnose von aneuploidie durch sequenzierung
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
NZ598600A (en) 2009-08-27 2014-03-28 Kyoko Endo Therapeutic agent for rhinitis
JP5728488B2 (ja) * 2009-11-13 2015-06-03 ビージー メディシン， インコーポレイテッド 心筋梗塞のリスクファクターおよび予測
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
WO2012013597A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
US8778699B2 (en) 2010-08-04 2014-07-15 Idexx Laboratories, Inc. Detection of degradation products of canine NT-proBNP
EP2658979B1 (de) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Zusammensetzungen mit natriuretischen peptiden und verwendungsverfahren dafür
WO2012115772A2 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
EP2715353B1 (de) 2011-05-31 2016-08-24 IDEXX Laboratories, Inc. Nachweis von abbauprodukten von felinem nt-probnp
EP2751136B1 (de) 2011-08-30 2017-10-18 Mayo Foundation For Medical Education And Research Natriuretische polypeptide
EP2750697A4 (de) 2011-09-02 2015-03-25 Medtronic Inc Chimäre natriuretische peptidzusammensetzungen und verfahren zu ihrer herstellung
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN107709352A (zh) * 2015-05-29 2018-02-16 Igisu株式会社 环肽以及含有该环肽的药物、外用剂和化妆品
MX2018002121A (es) 2015-08-17 2018-06-18 Alexion Pharma Inc Elaboracion de fosfatasas alcalinas.
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (de) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei kindern
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573A4 (de) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
US11224637B2 (en) 2017-03-31 2022-01-18 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
MX2022005676A (es) 2019-11-13 2022-10-27 Amunix Pharmaceuticals Inc Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos.
US11419917B2 (en) 2020-04-07 2022-08-23 Drora Shevy Treatment for SARS-CoV-2 and other coronaviruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572173B2 (en) * 1983-08-29 1988-05-05 Institut De Recherches Cliniques De Montreal Natriuretic factors
US4496544A (en) * 1983-11-10 1985-01-29 Washington University Atrial Peptides
US4557864A (en) * 1984-01-10 1985-12-10 Washington University Atrial peptides
US4508712A (en) * 1984-01-10 1985-04-02 Washington University Atrial peptide
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
AU4292785A (en) * 1984-04-24 1985-11-15 Salk Institute For Biological Studies, The Atrial peptide analogs
US4609725A (en) * 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
DE3509958A1 (de) * 1985-03-20 1986-09-25 Bayer Ag, 5090 Leverkusen Monoklonale antikoerper gegen atriale, natriuretische peptide vom menschen
EP0246795A3 (de) * 1986-05-20 1990-04-04 Advanced Peptide Development Limited Synthetische natriuretische Peptide
US4673285A (en) * 1986-05-23 1987-06-16 Xerox Corporation Optical scanning of duplex documents
JPS63107997A (ja) * 1986-09-18 1988-05-12 Mitsubishi Kasei Corp ペプチド
US4804650A (en) * 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
JP2544929B2 (ja) 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
US5674710A (en) 1997-10-07
US5948761A (en) 1999-09-07
IE68889B1 (en) 1996-07-24
AU3768189A (en) 1990-01-05
US20040002458A1 (en) 2004-01-01
DE68923878T2 (de) 1995-12-21
WO1989012069A1 (en) 1989-12-14
US6897030B2 (en) 2005-05-24
US20060030004A1 (en) 2006-02-09
US6974861B2 (en) 2005-12-13
JPH03505280A (ja) 1991-11-21
EP0418308A4 (en) 1991-11-13
EP0418308A1 (de) 1991-03-27
US20060160150A1 (en) 2006-07-20
CA1339210C (en) 1997-08-05
JP2511160B2 (ja) 1996-06-26
EP0418308B1 (de) 1995-08-16
US20030109430A1 (en) 2003-06-12
IE891792L (en) 1989-11-30
US7179790B2 (en) 2007-02-20
ATE126522T1 (de) 1995-09-15
US6586396B1 (en) 2003-07-01

Similar Documents

Publication Publication Date Title
DE68923878T2 (de) Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide.
Goodman et al. Identification and location of brain protein 4.1
US7361738B2 (en) Megakaryocyte stimulating factors
DE69433301T2 (de) Methoden zur erhöhung der biologischen aktivität von chemokinen
EP0786474A1 (de) Rekombinanter Abkömmling des menschlichen Faktors VIII
KR100393508B1 (ko) 인간 인터루킨 4의 안타고니스트 또는 부분적 아고니스트로서의 신규hIL-4 변이단백질
RU2009130434A (ru) Рекомбинантные молекулы лубрицина и их использование
RU2007110981A (ru) Урокортин iii и его использование
DE170917T1 (de) Neues derivat des humangammainterferon-polypeptids.
Lustbader et al. Characterization of the expression products of recombinant human choriogonadotropin and subunits.
ATE195344T1 (de) Gereinigtes interleukin-1 und für interleukin-1 kodierende dns und deren herstellung, solche dns enthaltende vektoren und deren herstellung und verwendung zum transformieren von wirten, die die expression von interleukin-1 zulassen
DE69120626T2 (de) Polypeptid
EP0652903B1 (de) Neues menschliches, rekombinantes interferon gamma
TW570801B (en) Osteoclastgenic inhibitory agent
US5756458A (en) Stabilized potent GRF analogs
Negro et al. Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli
Harper et al. Human class 1 heparin-binding growth factor: structure and homology to bovine acidic brain fibroblast growth factor
EP0306870A2 (de) Gamma-Interferon-Derivate, Herstellungsverfahren, Vektoren dafür und Arzneimittel daraus
RU2096416C1 (ru) Производные пептидов - аналоги grf или их нетоксичные соли
NZ227770A (en) Growth hormone releasing factor (grf) peptide containing a cysteic acid residue in position 3 or 25
Nishimura et al. Role of leucine residues in the C‐terminal region of human interleukin‐6 in the biological activity
CA2026776A1 (en) Stabilized, potent grf analogs
Nishikawa et al. 27 amino acid residues can be deleted from the N‐terminus of human lymphotoxin without impairment of its cytotoxic activity
JPH01106827A (ja) ヒトｂｃｄｆを含有する神経系障害治療剤
WO1992008473A1 (en) Therapeutic use of fibroblast growth factor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition